Alfaqih, M., Nelson, E. R., Liu, W., Safi, R., Jasper, J. S., Macias, E., … Freedland, S. (2016). CYP27A1/27HC/SREBP2 axis is a novel therapeutic target in prostate cancer. In European Journal of Cancer (Vol. 69, pp. S42–S43). Elsevier BV. https://doi.org/10.1016/s0959-8049(16)32708-3

Alfaqih, M., E. R. Nelson, W. Liu, R. Safi, J. S. Jasper, E. Macias, J. Geradts, C. Y. Chang, D. P. McDonnell, and S. Freedland. “CYP27A1/27HC/SREBP2 axis is a novel therapeutic target in prostate cancer.” In European Journal of Cancer, 69:S42–43. Elsevier BV, 2016. https://doi.org/10.1016/s0959-8049(16)32708-3.

Alfaqih M, Nelson ER, Liu W, Safi R, Jasper JS, Macias E, et al. CYP27A1/27HC/SREBP2 axis is a novel therapeutic target in prostate cancer. In: European Journal of Cancer. Elsevier BV; 2016. p. S42–3.

Alfaqih, M., et al. “CYP27A1/27HC/SREBP2 axis is a novel therapeutic target in prostate cancer.” European Journal of Cancer, vol. 69, Elsevier BV, 2016, pp. S42–43. Crossref, doi:10.1016/s0959-8049(16)32708-3.

Alfaqih M, Nelson ER, Liu W, Safi R, Jasper JS, Macias E, Geradts J, Chang CY, McDonnell DP, Freedland S. CYP27A1/27HC/SREBP2 axis is a novel therapeutic target in prostate cancer. European Journal of Cancer. Elsevier BV; 2016. p. S42–S43.